British Biotech calls in Fellner to kick start industry consolidation
Thursday 05 December 2002
Peter Fellner, currently chief executive of Celltech, has been appointed chairman of British Biotech and promised to kick start consolidation in the bombed out biotech sector.
He will initially take a non-executive role but is expected to move into an executive post next spring to steer British Biotech into a vital merger.
He unveiled ambitious plans to use the pioneering biotech company as a "nucleus" for a group combining several of the UK's smaller quoted drug developers.
"British Biotech has a strong balance sheet and embedded within the company are groups of high quality people working in clinical development," he said. "I am quite attracted by the idea of using it as a consolidation vehicle.
"It will be a challenge, but the environment for biotech currently is more difficult than I have known since I joined it in 1990, and it looks as if these difficulties will go on longer. That will be a catalyst to consolidation this time."
British Biotech has a £43m cash pile but no products anywhere near launch. Other companies in the sector have more advanced drugs but are burning cash trying to prove they work.
British Biotech reduced its interim losses to £8.1m in the six months to 31 October from £8.4m last year by selling many of its pre-clinical development facilities and cutting costs.
Mr Fellner argued that a string of deals could create a company with critical mass and better able to attract funding from shareholders or product licensees. Investors expressed their enthusiasm by chasing British Biotech shares up 29 per cent to 4.5p.
They peaked at 145p in 1998 but the company's supposed wonder drug for cancer, marimastat, failed to work and a previous management was ousted after claims that it failed to give timely information to shareholders on marimastat's disappointing performance in clinical trials. The company is still being threatened with legal action from lawyers representing some shareholders but no formal proceedings have begun.
Mr Fellner dismissed suggestions this potential liability could scupper his plans to woo merger partners, saying he had taken advice and concluded the claims were groundless. British Biotech said there has been greater interest from other biotech players since the departure, in October, of Elliot Goldstein, its chief executive.
Mr Fellner replaces Christopher Hampson, who retires at the end of the month, but will only move into an executive role when he is able to step back from the chief executive post at Celltech.
- 1 Sainsbury's '50p challenge' poster telling staff to encourage customers to spend more placed in shop window instead of staff room
- 2 Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
- 3 Isis an hour away from Baghdad - with no sign of Iraq army being able to make a successful counter-attack
- 4 Yes, the iPhone 6 is a miracle, but it's Apple's tax affairs that deserve a double take
- 5 Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
Isis could become 'world’s first truly terrorist state' and bomb UK with nuclear and chemical weapons, Theresa May warns
Car tax disc changes: Five facts you never knew about your (almost obsolete) tax disc
Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
Isis an hour away from Baghdad - with no sign of Iraq army being able to make a successful counter-attack
Isis, we are told, is a 'clear and dangerous threat to our way of life'. I’m sorry, but I just don’t buy it
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
The Osborne Ultimatum: Chancellor’s benefits freeze bombshell will affect ten million households
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Should gay sex be illegal? 16% of Britons think so
Mark Reckless becomes second Tory MP to defect to Ukip in a month
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...